Microbial Vesicles for Drug Delivery via Extracellular Vesiculation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Commercial therapeutic and nutraceutical agents often have low bioavailability and can cause side effects due to their purified form, leading to increased dosages and drug resistance, as they lack specific cellular chaperones for targeted delivery.
Innovation Solution
Administering initial agent molecules to microbes for extracellular vesiculation, generating microbial vesicles that contain and stabilize the molecules, allowing for targeted and efficient uptake by host cells, thereby enhancing bioavailability and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If therapeutic agents are packaged as purified compounds, then manufacturing precision is improved, but bioavailability deteriorates
Solution Approach 1:
The patent uses host cell machinery as an intermediary system to convert purified chemical prodrugs into active therapeutic forms within the host organism. The host cell's metabolic pathways serve as the conversion mechanism, bridging the gap between purified prodrugs and active drugs, thereby improving bioavailability while maintaining manufacturing precision.
Solution Approach 2:
The patent applies preliminary action by pre-converting therapeutic agents into prodrug forms that can be stored and transported in purified state, then relying on host cell metabolism to activate them in situ. This preliminary preparation allows the therapeutic agent to be manufactured with high precision while the activation step occurs naturally within the host, resolving the bioavailability issue.
2Reliability
If higher dosages are administered to overcome low bioavailability, then therapeutic efficacy is improved, but harmful factors increase
Solution Approach 1:
The host cell acts as an intermediary that selectively converts prodrugs into active therapeutic agents only where needed, avoiding systemic exposure to high doses. This targeted conversion mechanism improves therapeutic efficacy at the site of action while reducing side effects and toxicity associated with higher dosages.
Solution Approach 2:
The patent implements local quality by enabling therapeutic activation specifically within host cells at the target site. The prodrug conversion occurs locally where the host cell's metabolic machinery is present, concentrating the therapeutic effect where needed while minimizing exposure to healthy tissues and reducing harmful side effects.
3Manufacturing precision
If purified chemical forms are used, then manufacturing precision is improved, but absorption and uptake deteriorate
Solution Approach 1:
The host cell serves as an intermediary that facilitates the conversion and uptake of purified prodrugs. The host cell's natural transport and metabolic systems mediate the absorption process, allowing highly purified prodrugs to be efficiently taken up and converted into active therapeutic forms, thereby resolving the absorption issue while maintaining manufacturing precision.
Solution Approach 2:
The patent applies parameter changes by transforming the chemical state of the therapeutic agent from an inactive prodrug form to an active drug form within the host cell. This parameter transformation (chemical conversion) enhances absorption and uptake efficiency while the prodrug maintains its purified state during manufacturing and storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly improves drug efficacy, reduces dosage requirements, eliminates toxicity and resistance, and ensures complete absorption, minimizing environmental contamination.
Implementation Method 1
applying the initial agent molecules to microbes for extracellular vesiculation. Microbial vesicles are generated which contain the initial agent molecules by the microbes
Data Source
AI summary
A method comprises preparing initial agent molecules and applying the initial agent molecules to microbes for extracellular vesiculation. Microbial vesicles are generated which contain the initial agent molecules by the microbes. The packaged microbial vesicles are then administered to a host organism. By administering the initial agent molecules as a microbial vesicle package, binding proteins for the initial agent molecules may be co-administered, and cells may uptake numerous initial agent molecules concurrently.